capivasertib,Fulvestrant,AZD5363
astrazeneca,otsuka
['capivasertib', 'breast']
presenting now at #asco22: updated results from faktion
#fulvestrant + #capivasertib vs placebo after relapse or progression in metastatic, oestrogen receptor-positive, her2-negative #breastcancer: a randomised, phase 2 trial 
The Lancet Oncology is the global leader in clinical oncology publishing peer-reviewed research and reviews, comment, news, and Commissions. IF=41.316